AROW
Arrow Financial Corporation
AROW trails on the overall score without a compensating advantage in the available component scores.
BAC
Bank of America Corporation
BAC has the edge over AROW overall, supported by stronger fundamentals and stronger modeled upside.
AROW Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
AROW's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like AROW.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
AROW PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.3x | $38.68 | — |
| Cheap | 11x | $29.38 | -24% |
| Fair | 13x | $33.92 | -12% |
| Expensive | 15x | $39.77 | +2.8% |
| Current | 15x | $38.68 | — |
Historical ranges are pointers, not guarantees.
AROW's PE is in its expensive range at 15x. If earnings grow as analysts expect, today's price would be 9.3x next year's earnings, in its cheap range.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over AROW in the historical PE scenario, which offers more potential upside but is not a forecast.
AROW Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for AROW, but weaker profitability.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over AROW on the outlook, with more favorable profitability expectations.
AROW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.16 | +58% |
| Q3 2026 | $2.64 | +28% |
| Q2 2026 | $3.10 | +69% |
| Q1 2026 | $3.09 | +82% |
| Q4 2025 | $2.65 | +50% |
| Q3 2025 | $2.07 | +7.3% |
| Q2 2025 | $1.83 | -1.6% |
| Q1 2025 | $1.70 | +0.6% |
| Q4 2024 | $1.77 | +1.7% |
AROW earned $2.64 per share over the past year, up 28% from the year before.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over AROW on earnings, with more consistent year-over-year improvement.
AROW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $35M | +7.1% |
| Q1 2024 | $34.3M | -1.3% |
| Q4 2023 | $33.1M | -12% |
| Q3 2023 | $33.4M | -14% |
| Q2 2023 | $32.7M | -11% |
| Q1 2023 | $34.8M | -3.4% |
| Q4 2022 | $37.7M | +8.5% |
| Q3 2022 | $38.7M | +6.6% |
AROW has the stronger quarterly revenue trend. Revenue is up 7.1% for AROW versus up 6.7% for BAC.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2019 | 41% | N/A |
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
AROW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.8M | +31% |
| Q2 2026 | $11.6M | +40% |
| Q1 2026 | $13.9M | +58% |
| Q4 2025 | $4.8M | +18% |
| Q3 2025 | $14.3M | +77% |
| Q2 2025 | $8.3M | +10% |
| Q1 2025 | $8.8M | -4.3% |
| Q4 2024 | $4.1M | +$21M |
AROW has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
AROW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +12% | +2M shares |
| 1 year | +13% | +2.1M shares |
| 3 years | +8.3% | +1.4M shares |
| 5 years | +8.2% | +1.4M shares |
| Available history | +9.5% | +1.6M shares |
AROW has 18M diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1M |
| Q2 2026 | $370,000 |
| Q1 2026 | $113,000 |
| Q4 2025 | $154,000 |
| Q3 2025 | $1.4M |
| Q2 2025 | $5.2M |
| Q1 2025 | $3.5M |
| Q4 2024 | $265,000 |
AROW spent $2M buying back its own shares over the past year, down 84% from the year before.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over AROW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
AROW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 3.1x | Elevated |
AROW's net debt is about 3.1 years of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like AROW.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
AROW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.7 | Neutral |
| Stochastic | 55.0 | Neutral |
AROW's weekly RSI is 55 (neutral) and its Stochastic is 55 (neutral).
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
AROW PE vs Financial Services Sector
| Metric | AROW | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 13% above |
| PE % | 77 | 63 | 14 pts above |
AROW is trading at 15x earnings, a 13% premium to the Financial Services sector's median of 13x.
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over AROW on valuation relative to its sector.
AROW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.8 | 2.3% above |
| 20 week MA | $38.9 | 0.5% below |
| 50 week MA | $36.4 | 6.2% above |
| 100 week MA | $31.8 | 22% above |
| 200 week MA | $28.4 | 36% above |
AROW has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
AROW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.4 | $29.4 | -19% |
| 2021 | $29.4 | $34.2 | +17% |
| 2022 | $34.2 | $34.4 | +0.4% |
| 2023 | $34.4 | $27.9 | -19% |
| 2024 | $27.9 | $28.5 | +2% |
| 2025 | $28.5 | $31.5 | +10% |
| 2026 YTD | $31.5 | $38.7 | +23% |
AROW has the edge over BAC on returns for 2026, with the stronger performance.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.